<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03269435</url>
  </required_header>
  <id_info>
    <org_study_id>2017-8249</org_study_id>
    <nct_id>NCT03269435</nct_id>
  </id_info>
  <brief_title>Greater Occipital Nerve Block Versus Metoclopramide</brief_title>
  <official_title>A Randomized Trial of Greater Occipital Nerve Block With Bupivacaine Versus Intravenous Metoclopramide for Acute Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are comparing a type of nerve block called greater occipital nerve block versus standard
      therapy among patients who present to an emergency department for acute migraine. This is a
      randomized, double-blind, double dummy study. The greater occipital nerve block will be
      performed bilaterally with bupivacaine 0.5%. Standard therapy is metoclopramide 10mg IV.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double dummy design with IV placebo and placebo nerve block</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained headache relief</measure>
    <time_frame>48 hours</time_frame>
    <description>Headache level = mild or none. Achieved in emergency department and maintained for 48 hours without rescue medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained headache freedom</measure>
    <time_frame>48 hours</time_frame>
    <description>Headache = none, achieved in emergency department and maintained for 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ED dwell time</measure>
    <time_frame>48 hours</time_frame>
    <description>Length of stay in ED: randomization to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in 0-10 pain score</measure>
    <time_frame>one hour</time_frame>
    <description>Pain score assessed at baseline and one hour</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Greater Occipital Nerve Block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bilateral greater occipital nerve block with bupivacaine 0.5%
+ Normal saline IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoclopramide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoclopramide 10mg IV
+ Bilateral greater occipital nerve block with normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Greater occipital nerve block with bupivacaine</intervention_name>
    <description>This is a type of peripheral nerve block. 3cc of 0.5% bupivacaine will be injected adjacent to the greater occipital nerve block blaterally</description>
    <arm_group_label>Greater Occipital Nerve Block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopramide</intervention_name>
    <description>Metoclopramide 10mg IV will be administered over 15 minutes</description>
    <arm_group_label>Metoclopramide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Eligible patients are adults who present with an acute moderate or severe headache meeting
        migraine headache criteria, as defined by the International Classification of Headache
        Disorders-3Î² (1.1, migraine without aura). Patients who meet criteria for Probable Migraine
        without Aura (1.5.1) will also be included, provided they have had at least one similar
        attack previously.

        Exclusion Criteria:

        Patients will be excluded if informed consent cannot be obtained, if there is concern for a
        secondary cause of headache, if the maximum documented temperature is greater than 100.3
        degrees, for a new objective neurologic abnormality, skull defect, suspected infection
        overlying injection site, known bleeding disorder, ongoing use of anti-platelet agents
        including P2Y12 platelet inhibitors (clopidogrel, prasugrel, ticagrelor), heparins,
        warfarin, or 10a inhibitors (rivaroxaban, apixaban, edoxaban, fondaparinux), prior
        treatment with a greater occipital nerve block, allergy to the investigational medications,
        pheochromocytoma, seizure disorder, Parkinson's disease, use of MAO inhibitors, and use of
        anti-rejection transplant medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>self-described</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin W Friedman, MD, MS</last_name>
      <phone>718-920-6626</phone>
      <email>befriedm@montefiore.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2017</study_first_submitted>
  <study_first_submitted_qc>August 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2017</study_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Benjamin Friedman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

